Cancer

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in…

2 weeks ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in…

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 weeks ago

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation

Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now…

2 weeks ago

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant…

2 weeks ago

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant…

2 weeks ago

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with…

2 weeks ago

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with…

2 weeks ago